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Summary.-Experiments were conducted to determine the dose response of rat
bladder urothelium to a range of different single and fractionated intravesicular
doses of the carcinogen, N-methyl-N-nitrosourea (MNU). A dose-related response
of bladder-tumour incidence to single graded doses of MNU was found, and a
threshold dose suitable for use in multistage carcinogenesis experiments was
derived from these data. For any given total dose of MNU, the tumour incidence was
greater if the MNU had been administered in several small fractions than if it had
been administered in fewer larger ones. Extending the interval between doses did
not reduce the tumour incidence. It is argued that these results support the multi-
stage theory of carcinogenesis. The histopathology and cell-surface alterations
which characterize the development of MNU-induced bladder cancer are described
and the contribution of hyperplasia and calculi are discussed.
THE INTRAVESICULAR INSTILLATION of
fractionated doses of N-methyl-N-nitro-
sourea (MNU) to induce rat bladder
cancer (Hicks & Wakefield, 1972) was
developed to provide a more controllable
animal bladder-cancer model than those
which were then available, using car-
cinogens in the diet or drinking water.
MNU is a direct-acting carcinogen which
does not need to be metabolized to an
active intermediate, and produces persist-
ent, multiple methylation of the DNA in
tissues with which it comes in contact
(Frei & Lawley, 1975; Cox & Irving, 1976).
It decomposes spontaneously in aqueous
solution at a rate proportional to pH, and
its half-life in the body was reported to be
about 5-10 min (Swann, 1968). It is thus
practicable to administer short pulses
directly to the bladder via a urethral
catheter, and to investigate the dose-
related response of the urothelium to this
model alkylating carcinogen.
The development of this rat bladder
model lasted for about 4 years with a
single batch of MNU, sample A. This
sample was generously provided by P. N.
Magee, who had demonstrated in vivo its
carcinogenic activity in other rat tissues.
It had been obtained from the Schuchardt
Chemical Company and was recrystallized
at the MRC Toxicology Institute, Carshal-
ton, to give a yellow crystalline prepara-
tion with a melting point of 122-124°C.
This sample gave consistent results, such
that a single dose of < 2 mg produced no
urothelial tumours, a single dose of >3
mg was lethal, but 6 mg administered in 4
fractions of 1P5 mg at 2-weekly intervals
produced a 100% incidence of bladder
cancer (Hicks & Wakefield, 1972). Since
the first fraction of 1P5 mg was itself
sub-carcinogenic, in subsequent studies
into the multistage nature of carcino-
genesis in the urinary bladder this dose
was used to initiate the urothelium
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before studying the effect of other pro-
moting agents (Hicks et al., 1975, 1978;
Hicks & Chowaniec, 1977; Hicks, 1980).
After finishing the first batch of MNU
(sample A), single doses of 1P5 mg or 2*0
mg of other batches, used both here and
in other laboratories, proved to be carcino-
genic and produced bladder-cancer inci-
dences of - 20% and - 400o respectively
(Hicks et al., 1978; Mohr et al., 1979;
Hicks, 1980; Hooson et al., 1980). This
suggested that the MNU sample A may
have partially decomposed before we
started using it, but its activity had then
remained stable. It thus proved necessary
to recalibrate the response of the urinary
bladder to this carcinogen and to re-
determine an appropriate threshold dose.
This paper reports the data from which a
threshold dose has been selected for
further work on multistage carcinogenesis
using the MNU Wistar rat bladder model.
It provides new information on the reac-
tion of the urothelium to different frac-
tionated doses and the persistence of the
initiating event. The histopathology and
alterations in cell structure which charac-
terize the development of MNU-induced
bladder cancer are also described and the
significance of hyperplasia explored.
MATERIALS AND METHODS
MNU.-MNNU was synthesized by Dr A. K.
Wallis in the Courtauld Institute of Bio-
chemistry by the method of Werner (1919).
The fine, pale-yellow crystalline product was
checked for purity by melting-point deter-
mination (m.p. = 122-124°C with decomposi-
tion from 110°C) and by high-pressure
liquid chromatography (HPLC). It was
separated by reverse phase HPLC using a
6-2mm internal diameter x25 cm Dupont
Zorbax octadecyltrimethoxysilane column
with 15% methanol:85% water as solvent
(1-5 cm3/min) and was quantified from its
UV absorbance at 231 nm. The freshly
prepared batch of MNIJ was divided into
small aliquots weighing between 4 and 100
mg stored in light-proof, screw-capped vials
at -20°C. Analysis of aliquots withdrawn
from this batch over 3 years confirmed that
the MNU was completely stable under these
storage conditions.
Animals-.Specific-pathogen-free female
Wistar rats, free from the bladder parasite
Trichosomides crassicauda, were used. They
were caged in groups of 5 in rooms kept at
19-22°C with a relative humidity of 50-60%,
and were maintained on Dixon's standard
pelleted 41B diet and tap water ad libitum.
The animals were 6-8 weeks old at the start
of treatment, and were killed after 2 years,
or earlier if they appeared moribund or
symptoms such as haematuria or a palpable
pelvic mass developed.
Carcinogen dosing.-Each pre-weighed ali-
quot of MNU was brought overnight to 4°C.
A measured volume of citrate buffer (pH
7-0) was added to give the required concen-
tration of carcinogen, and the solution
stirred in the re-sealed vial with a magnetic
flea to ensure rapid dissolution of MNU. The
resulting solution was used for dosing animals
during the next 30 min only, and the residue
then discarded into IN NaOH. Where large
numbers of animals were dosed in one
session, several fresh solutions of MNU were
prepared at intervals as required.
Catheters were made from 4cm lengths of
Portex tubing (PP1O, Portex Ltd., Hythe,
Kent) and sterilized in 70% ethanol. Rats
were anaesthetized by i.p. veterinary Nem-
butal, and a catheter inserted via the urethra
into the bladder of each animal. Before
instillation, micturition was induced by appli-
cation of gentle pressure to the lower abdo-
men. This ensured that the concentration of
carcinogen contacting the urothelial surface
was not altered by dilution with urine in the
bladder. The concentration of MNU was
selected so that the required dose could be
instilled in a volume of 041 cm3 or 0-15 cm3,
using a graduated syringe with a fine needle
which fitted into the end of the catheter.
After dosing, the catheter was withdrawn
from each bladder, and the animals returned
to a cage where they were kept warm during
recovery. Doses of 0-1 mg, 0 5 mg, 1-0 mg
or 1-5 mg MNU were given per animal. Both
single- and multiple-dose experiments were
conducted. Full details of treatments and
numbers of animals per group are given in
Tables I & II. The experiments were arranged
as 2 major sets comprising numbers 1 to 3
and 4 to 7 (Tables I & II). Animals were
randomly allocated on arrival to experiments
withinthese sets. Wherea series oftreatments
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TABLE I.-Treatment protocol: Set 1
No. of animals
at start
37
24
24
24
87*
30
24
48
No.
usable
33
17
20
20
81
26
19
46
TABLE II.-Treatment protocol: Set 2
No. of
animals
at start
36
44
36
34
48
55
37
64
No. usable
32
37
30
28
45
48
30
51
No. of
tumour-bearing
bladders
(0)
2 (6)
6 (35)
9 (45)
17 (75)
15 (19)
20 (77)
19 (100)
0 (0)
No. of
tumour-bearing
bladders
(%)
1 (3)
2 (5)
5 (16)
5 (18)
3 (7)
19 (40)
5 (17)
1 (2)
* The starting number for this group was deliberately high to increase confidence in the
results obtained with a single dose of 1-5 mg. This dose of the previous batch of MNU,
sample A, had had "no effect" in our earlier experiments.
with a given fraction size took place (e.g.
0-1 mg MNU; experiments 4a, b, c, d, and e),
after the appropriate number of doses had
been administered animals not destined for
further treatment were again randomly
selected.
Histologyand electron microscopy.-Animals
were killed by cervical dislocation and exam-
ined for the presence oftumours. The urinary
bladder was exposed, emptied by gentle
pressure and, after clamping the urethra,
cacodylate-buffered 4% formaldehyde (pH
7.3) was injected to fill but not overdistend
the bladder. The serosal surface was then
bathed with the fixative, and after 4 min the
bladder was excised, opened and inspected
for macroscopic abnormalities (e.g., thickened
areas, tumours and calculi). Representative
samples were either further fixed in formalin
for light microscopy or cut into 1mm3
blocks and post-fixed in cold cacodylate-
buffered 1% osmium tetroxide for electron
microscopy. Other organs were examined for
gross abnormalities, and the kidneys, lungs,
liver, uterus, spleen and pancreas routinely
processed for histology. All specimens for
histology were fixed in formalin, embed-
ded in paraffin wax, sectioned, and stained
with haematoxylin and eosin. Thin sections
( 80 nm) of Spurr-embedded bladder were
contrast-stained with uranyl acetate and
lead citrate for electron microscopy, and
semi-thin (1,um) sections stained with
toluidine blue for high-resolution light micro-
scopy. At least 3 blocks from each bladder
were examined by the latter method to
complement the results obtained by con-
ventional histology. The few animals that
were found dead were processed for histology
only.
RESULTS
Tumour incidence after single graded doses
of MNU
The incidence of bladder tumours
observed after single graded doses of
MNU is plotted in Fig. 1. Two control
Experiment
No.
I a
b
c
d
2 a
b
c
3
Treatment
(mg MNU)
x0 05
2 x 0 5
3 x 0 5
4x0 5
1 x 1-5
2x 1-5
3x 1-5
0 (controls)
Experiment
No.
4 a
b
c
d
0
5
6
7
Treatment
(mg MNU)
1x 0.1
2x0 1
3 x 0 1
4x 01
2 x 0 -1
(25-week
interval)
2 x 0 5
(25-week
interval)
1 x 1*0
0 (controls)
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FiG. I. Rat urinary bladder tumour
incidence in re3ponse to single graded (loses
of MNU. (Two separate control groups
are shlowni for the zero (lose.)
groups were untreated. It can be seen
that as the amount of MNU administered
was increased, there was a progressive
rise in tumour incidence. However, even
at the highest dose, tumour incidence re-
inained low (19%). On the basis of these
data, a bladder-tumour incidence of 100%
appears to be unobtainable from a single
sub-lethal dose of this carcinogen.
Tumour incidence after multiple dose8 of
MNU
The effect of splitting a given total dose
into a series of smaller fractions was
investigated. Two, 3 and 4 consecutive
doses of 0-1 mg MNU were administered
to separate groups ofanimals. Correspond-
ing experiments were run using repeated
doses of 0'5 and 1 5 mg MNU. The
results (Fig. 2) show a clear relationship
between tumour incidence and the number
of doses in each case. For any given
number of doses, the tumour yield rises
as the dose level is increased, and with 3
doses of 1P5 mg tumour incidence is 100%.
Expressing the same results in terms ofthe
cumulative amount of MNU administered
(Fig. 3), it can be seen that for any given
total dose of MNU, tumour incidence was
C
*R 60
C
E 40 o
20
Ox
0 1 2 3
No. of Doses of MNU
FIG. 2. Bladder tumouir incidence in response
to multiple doses (at 2-week intervals) of
0-1 (*) 0 5 (0) and 1-5 (-) mg MNU.
(Open symbols show results from experi-
ments with an interval of 25 weeks between
the (loses.)
100
80 -
60 -
CD 40 F
20 -
L
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Cumulative Administered Dose of MNU (mg)
0
FIG. 3. Same data as in Fig. 2, plotted
against cumulative dose of MNU. (The
symbol x represents tumour incidence
after a single dose of 1-0 mg MNU.)
greater after smaller fractions of MNU
than after larger fractions.
Effect of interval betweenfractions
The experimental groups given 2 doses
of 0'1 and 0.5 mg MNU 2 weeks apart
were compared with corresponding groups
in which the same doses were separated by
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25 weeks. This extended interval did not
Hperprasias reduce the tumour incidence (Fig. 2).
Incidence of hyperplasia
MNU-treated bladders showed a much
higher incidence of hyperplasia than the
controls (Fig. 4). Though the response was
dose-related, the increase in hyperplasia
Tumours with dose was less marked with single
graded doses (Fig. 4A) owing to the high
incidence even at the lowest dose (0.1 mg).
- Presence of calculi
Thirty-two per cent of tumour-bearing
bladders contained calculi or showed
calcification, but this incidence was in-
dependent of MNU dose. Calculi were not
Hyperplasias found in the absence of a tumour in the
present series ofexperiments. They varied
in form and number, 2 extreme ex-
amples being illustrated in Fig. 5.
Histopathology
Short-term effects.-To examine the
Tumours short-term effects of MNU treatment on
* the bladder, groups of rats separate from
the main series of experiments were given
single doses of0.1, 0-2, 0-3, 0'4 and 0-5 mg
MNU. Even at the lowest dose, toxic
o 1 2 3 4 damage (notably intracellular oedema
No. of MNU Doses and stripping of superficial cells) was
4.-Comparison of incidences of hyper- evident at 1-3 days after treatment, and
lasias and tumours after single graded mild focal hyperplasia up to 3 weeks. A
Dses of MNU (A) and multiple doses of
1 mg MNU (B). progressively more marked response was
FIG. 5.-Calculi from tumour-bearing bladders. A, single calculus; B, multiple calculi from a single
bladder (treatment; 2 x 0 5 mg MNU with a 25-week interval).
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found as the dose increased, though even
at 0 5 mg the effects remained mild and
focal, and were detected only after
thorough searching.
Terminal findings.-Although the inci-
dence of focal and/or widespread urothe-
lial hyperplasia and neoplasia depended
on the number of doses and quantity of
MNU administered, the principal patho-
logical features were common to all the
experimental groups. Most tumours were
of the transitional-cell type, though 5%0
were of connective-tissue origin. Excep-
tionally, both carcinoma and sarcoma
were present in the same bladder.
Some animals in the groups receiving
single doses or multiple low doses of MNU
retained a normal pattern of urothelial
differentiation (Fig. 6). In the 0 1mg
series, for example, the proportion of
bladders with only normal-looking urothe-
lium ranged from 53%0 in rats receiving a
single dose down to 14% in those treated
with 4 doses. A reduction in the number of
bladders with normal differentiation was
also found as single graded levels were
increased (e.g.. 0 5 mg MNU, 42% normal;
1.0 mg MNU, 26% normal). It is note-
worthy that although most control blad-
ders showed normal urothelial differentia-
tion, 10% had mild focal hyperplasia,
and 1 tumour was found at the end of the
2-year period.
Hyperplasias were categorized as simple,
papillary or nodular, though gradations
between these forms and combinations of
them were common in all the treated
groups. Simple hyperplasias were
characterized by the presence of a thick-
ened urothelium in which an orderly
differentiation from basal to superficial
cell layers was apparent. Superficial cells
were sometimes flattened, though not
necessarily fully differentiated, and blood
vessels were often conspicuous at the
base of the urothelium. As the thickness
of the urothelium increased, there was a
loss of cellular organization, and blood
vessels were frequently found growing up
into or arching within the urothelium.
Some hyperplasias displayed a distinct
nodular growth pattern at an early stage
(Fig. 7). Further development of the
nodules was associated with increasing
cellular pleomorphism and infiltration of
urothelial cells into the stroma (Fig. 8).
Lesions at this stage were classified as
transitional-cell carcinoma with a nodular
growth pattern.
Papillary hyperplasias were more com-
mon than the nodular variety, and were
associated with an exophytic prolifera-
tion of blood vessels towards the bladder
lumen. Even in mildly hyperplastic blad-
ders, early blood-vessel development and
marked atypia and disorganization in
the neighbouring urothelial cells were
sometimes seen (Fig. 9). It is a matter of
judgement whether the degree of cell
atypia is sufficient to classify this type of
lesion as carcinoma in situ. Such "early"
lesions were frequently associated with
well developed papillary tumours, like
those illustrated in Figs. 10 and 11. Fig.
10 shows part of an extensive early
papillary tumour, and Fig. 11 a discrete
localized one. In the latter, invasion has
taken place into the supporting stalk of
FIG. 6. Urothelium sbiowing normal differentiation into basal, intermediate and superficial cell
layers from an animal killed 2 years after receiving 3 x 0-1 mg MNU. No abnormality was detectecd
elsewhere in this bladder. Toluidine blue-stained semi-thin section. x 305.
FIT. 7.-Early nodular hyperplasia associated with sub-urothelial lymphocytic infiltration in an ani-
mal treated with 4 x 0*1 mg AINU. Toluidine blue. x 170.
FIG. 8. Part of a tumour with a nodular growth pattern from an animal treated with 2 x 0 *5 mg
MNU (25 weeks between doses). H. & E., wax section. x 110.
FIG. 9. Mildly hyperplastic urothelium showing focal areas of atypical cells in which there is a
disorientated and differential growth pattern. (Treatment: 4 x 0 1 mg MNU.) Toluidine blue.
x 235.
Fic. 10. Part of an extensive early papillary tumour from an animal that received 4 x 0-1 mg
MNU. Toluidine blue. x 170.
FIG. 11. Small discrete papillary tumour from an animal treated with 2 x 0 5 mg MNU. Nests of
invasive cells penetrate into the tumour stalk. The surrounding urothelium is moderately hyper-
plastic. Toluidine blue. x 75.
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the tumour, but not below the level ofthe
surrounding hyperplastic urothelium.
In more advanced papillary tumours,
nests of urothelial cells were found in the
stroma below the tumour stalk (Fig. 12),
sometimes extending deep into the bladder
wall (Fig. 13). The invading cells often
appeared increasingly pleomorphic, bear-
ing little resemblance to the urothelial
cells from which they were derived (Fig.
14). Most of the papillary lesions, whether
or not there were invasive regions, were
well-differentiated transitional-cell tum-
ours and often showed areas of squamous
metaplasia (Fig. 15).
Cystitis cystica and adenocarcinomas
were not observed in these animals.
No metastases from the bladder tum-
ours were found in other organs, though a
few neoplasms were found in the uterus
and the kidneys of some of the MNU
treated animals.
A single untreated control rat developed
a bladder tumour, detected at 86 weeks
after the start of the experiment. This
animal also had an extensive papillary
tumour of the kidney calyx, associated
with a large kidney stone. Calculi were
also present in the bladder, but otherwise
no macroscopic abnormality was evident.
On microscopic examination, however, a
flat invasive transitional-cell tumour (P2)
which displayed focal regions of mucous
metaplasia was found. The surface urothe-
lium was of almost normal thickness but
invaginated as projections into the stroma
(Fig. 16). This growth pattern was rarely
found after MNU treatment.
Electron microscopy
A scalloped luminal-membrane profile
of semi-rigid concave plaque regions
separated by flexible interplaque peaks is
the hallmark of normal differentiation in
the urothelium, and was present in most
of the untreated control animals. Such a
structure was also typical of the carcino-
gen-treated bladders diagnosed as normal
by light microscopy, and was also seen
in some regions of normal appearance
from tumour-bearing bladders (Fig. 17).
Transitional-cell tumours displayed 2
characteristic structural features-pleo-
morphic microvilli and a prominent glyco-
calyx-at the luminal face of some but not
all surface cells. Often these structures
were associated with one another, though
this was not invariable. The tumour-
cell surface in Fig. 18, for example, has
abundant well-developed microvilli but
no glycocalyx, whereas the irregular but
non-microvillous surface depicted in Fig.
19 shows a conspicuous glycocalyx. Con-
siderable morphological variation in both
the microvilli and the glycocalyx was
found, though the exact form ofstructural
differentiation tended to remain constant
over the surface of a given cell. Some
microvilli consisted ofrather short, stubby
projections with knobby heads (Fig. 20)
and apparently developed from inter-
plaque regions of the luminal membrane,
as normal differentiation was lost. Glyco-
calyx material was more profuse over
the surface of microvilli than on the
intervening membrane regions, though it
was rarely completely excluded from them
(Figs. 20 and 21). The filaments comprising
the glycocalyx ranged from coarse
electron-dense beaded structures to fine
ones (Figs 19-22). Longer filaments were
often branched, and although the branches
FIG. 12. Papillary tumour with early stomal invasion. (2 x 0-5 mg MNU; 25 weeks between doses.)
H.&E. x160.
FIG. 13.-Invasive cords and nests of atypical urothelial cells deep in the bladder wall beneath an
advanced papillary tumour. (2 x 05 mg MNU with 25-week interval.) H. & E. x 100.
FIG. 14.-Detail of pleomorphic urothelial cells at invasive base of a tumour in an animal treated
with a single dose of 1-0 mg MNU. Toluidine blue. x 190.
FIG. 15. Squamous metaplasia and keratinization in part of a papillary tumour. (2 x 0*5 mg MNU
with 25-week interval.) Toluidine blue. x 145.
FIG. 16. Surface region from part of the flat invasive urothelial tumour found in a single control
animal. H. & E. x 155.
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usually remained of constant thickness,
sometimes a progressive reduction in the
diameter of each new branch was appa-
rent (Figs 20 and 21).
The single bladder tumour from the
control group also revealed short micro-
villi at the luminal surface which were
covered with a fine filamentous glyco-
calyx (Fig. 22).
DISCUSSION
MNU has a short (5-10 min) half-life
in the body (Swann, 1968), but its rate of
decay is pH-dependent, and at the normal
pH of rat urine (6.0-6.5; Chowaniec &
Hicks, 1979) it will persist much longer.
Using tritiated MNU and high-pressure
liquid chromatography, we had previously
demonstrated the half-life of MNU in
Hanks' balanced salt solution to be
- 300 min at pH 6-0, 150 minat pH 6-3
and 90 min at pH 6-5 (Knowles, Moore
and Hicks, umpublished). The MNU
solution instilled into the bladder in the
current experiments mixes with fresh
urine (pH 6 0-6'5) arriving from the
kidneys, and clearly persists long enough
to react with macromolecules in the
urothelial cell. Indeed, using our instilla-
tion technique, Cox & Irving (1977)
demonstrated temporary alkylation of
various bases in rat urothelial cell DNA,
and the persistence of 06-methylated
guanine with accumulation of the 06
product after repeated instillations of
MNU into the bladder. Provided the
method of preparation and instillation of
the MNU solution is carefully standard-
ized, our results demonstrate that any
pH-related decay does not confound the
dose-related response of the urothelium
to MNU.
As can be seen from Fig. 1, there is a
good dose-related response of the urinary
bladder to the carcinogenic effect of MNU
administered in single graded doses.
Furthermore it can be seen from Tables
I & II and Fig. 2 that the effect of re-
peated small doses of the carcinogen is
cumulative and that, using different
aliquots, there is a dose-response curve.
When the tumour incidence is plotted
against the total cumulative dose (Fig. 3)
it can be seen that for any given total
dose the tumour response is greater if the
MNU had been administered in the
smaller fractions. This reflects the dose-
related toxicity of MNU. Larger fractions
may transform more cells, but at the
same time fewer cells survive toxic
damage, so that the surviving population
available for reaction with subsequent
doses is progressively reduced.
Although much higher doses of the first
batch of MNU (sample A) had to be used
to obtain the same effect, a good dose-
related response had been obtained with
that preparation also (Hicks et al., 1978).
With sample A, 1P5 mg was sub-carcino-
genic, whereas 1-5 mg of later freshly
prepared samples of MNU (sample B)
produced a bladder cancer incidence
of 20%. Nevertheless, the results
obtained with sample A remain valid,
since there were always appropriate
concurrent controls, and the dose response
remained consistent for several years.
Fia. 17.-Thin-section electron micrograph showing the luminal face of an area of normal-looking
urothelium from a tumour-bearing bladder. The scalloped profile is identical to that seen in
untreated animals. (2 x 0 5 mg MNU; 25-week interval.) x 46,800.
FIG. 18.-EM of a tumour-cell surface from the same bladder as in Fig. 17. Long microvilli (in cross-
section) are abundant but no glycocalyx is present. x 25,200.
FIG. 19.-Elsewhere in the same tumour microvilli are absent at the surface but a prominent beaded
glycocalyx is visible. x 50,400.
FIG. 20.-This example further illustrates the variety of structural differentiation within the same
tumour. Here a fronded glycocalyx covers short microvilli, but is absent from the intervening
membrane. x 41,400.
FiG. 21.-Example of a beaded glycocalyx on short surface projections. (Tumour from animal
treated with 2 x 0 5 mg MNU; 25-week interval.) x 47,700.
FIG. 22.-Fine filamentous glycocalyx at the surface ofthe single control bladder tumour. x 75,600.
347N. J. SEVERS, S. H. BARNES, R. WRIGHT AND R. M. HICKS
Similar variability between different
batches of another carcinogen, N-(4-
(5-nitro-2-furyl)-2-thiazolyl) formamide
(FANFT) has been reported. In some
experiments, 6 weeks' feeding of 0 2%
dietary FANFT proved to be a sub-
threshold dose (Jacobs et al., 1977)
whereas in others it produced a 20%
bladder-tumour incidence (Cohen et al.,
1979). Again since concurrent controls
were used the results are valid for both
sets of experiments.
It was hoped that an absolute dose of
MNU (sample B) suitable for initiation in
multistage carcinogenesis could be derived
from the data in Figs 1 & 2. Ideally, such
a dose should be high enough to initiate
a large proportion of cells, but too low
to complete the subsequent promotion
and propagation stages of carcinogenesis.
In that situation, no tumours would
developed until the initiated cells were
acted upon by promoters or further doses
of a carcinogen. However, inspection of
Fig. 1 shows that there is no threshold
dose of sample B below which tumours
were completely absent. Furthermore, one
animal in a group of 51 controls also
develop a bladder tumour. This is the
only "spontaneous" bladder tumour ob-
served in our Wistar rat colony during 15
years, and in this instance may well have
been seeded from the transitional-cell
tumour found higher up in the urinary
tract in the renal pelvis. These findings
emphasize the difficulties in achieving
the ideal characteristics for a multistage-
carcinogenesis animal model in vivo. In
practice, determination of a true initiat-
ing dose may be unrealistic. A compromise
has to be made based on the minimum
tumour incidence induced by a single dose
that is consistent with a markedly in-
creased incidence on subsequent dosing.
On this basis, the present results suggest a
single treatment of 0 3-0 5 mg MNU as a
suitable threshold dose for studying multi-
stage carcinogenesis in the Wistar rat
model. It must be remembered, however,
that the persistence (and therefore the
effective dose) of MNU in the bladder
will be affected by urinary pH, and that
this in turn may be altered by diet.
Furthermore, different mouse strains are
known to have different susceptibilities
to individual carcinogens (Andervont &
Edgcomb, 1956; Festing, 1975) and the
same may well be true for different rat
strains. It may thus prove necessary to
adjust the threshold dose used in any
particular laboratory and for any particu-
lar strain of rat. In such experiments,
the requirement for concurrent controls
using the same batch of carcinogen
cannot be emphasized too strongly.
In the current series of experiments,
tumour incidence remained essentially
unchanged on extending the interval
between 2 doses of MNU, confirming that
the carcinogenic damage induced by the
first dose persists over a long period. This
is consistent both with the original
concept of initiation as a permanent
alteration to the cell (Berenblum, 1941)
and with the reported persistence of 06_
methyl-guanine in the DNA of MNU-
treated urothelium (Cox & Irving, 1977).
However, a reduced bladder-tumour inci-
dence was observed in another system in
which a delay was interposed between
initiation and promotion treatments. In
the FANFT model, when saccharin was
used as a promoter, fewer tumours were
found when 6 weeks were allowed between
the FANFT and saccharin treatments
than when no interval was given (Cohen
et al., 1979). In the same model, Arai
et al. (1977) demonstrated the promoting
activity of cyclophosphamide, but this
activity disappeared if administration was
delayed for 6 weeks after completion
of the FANFT treatment. Thus, in con-
trast to the carcinogenic damage induced
by MNU, some of the damage induced by
FANFT may be repaired.
The mild focal hyperplasia in 10% of
untreated bladders at the end of the 2-
year period indicates that the experi-
mental results should be interpreted
against a background ofage-related patho-
logical change. A few hyperplasias in
controlWistarmales (but notfemales) were
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recorded in previous experiments from
thislaboratory (Chowaniec & Hicks, 1979).
Our finding that the incidence of
hyperplasias as well as tumours is dose-
related (Fig. 4) supports the histopatho-
logical evidence that tumours develop
from hyperplastic lesions. However, not
all hyperplasias necessarily progress to
tumours, and the- exact significance of
hyperplasia in the biogenesis of tumours
remains under discussion. A "precursor-
product" relationship between persistent
hyperplasias (i.e. those persisting 9 months
or longer) and tumours which had devel-
oped 9 months later, was established
in 2-acetylaminofluorene (2-AAF)-treated
BALB/c mice, even though some early
hyperplasias in that system regress if
treatment is stopped (Littlefield et al.,
1979). The early hyperplasia (i.e. at 2
days to 3 weeks) afterasingle dose ofMNU
or a single dose of cyclophosphamide
rapidly regresses, and normal differentia-
tion is subsequently restored (Hicks &
Wakefield, 1972; Koss & Lavin, 1970).
Although a few of the hyperplasias
present at the end of the current experi-
ments could possibly have arisen as a
late temporary response (e.g. to the
irritant effect of a calculus) it seems
probable that most were of the persistent
type and, as in the 2-AAF system,
represent preneoplastic lesions potentially
leading to tumours. However, within the
time-scale of the experiments, clearly
only a small proportion of these hyper-
plasias is able to progress to tumours, as
is shown bv Fig. 4.
The irritant effect of calculi andthe con-
sequent increase in cellturnover is thought
to give a propagating stimulus to tumour
growth in the rodent bladder (Chapman
et al., 1973) and the presence of calculi in
one-third of the tumour-bearing bladders
in the present experiments is consistent
with this view. However, since the pre-
sence of calculi was not related to MNU
dose, and not only do some tumours
develop in the absence of calculi but also
calculi sometimes occur in tumour-free
bladders (Hicks & Chowaniec, 1978), the
presence ofa calculus cannot be considered
as obligatory to tumour formation (cf.
Clayson, 1974).
The hyperplastic and neoplastic lesions
of the urothelium induced by MNU
appear similar to those induced by other
bladdercarcinogens(e.g.FANFT, BBNand
brackenfern), and thepathways oftumour
development are probably common to all
these experimental systems (Kunze et al.,
1976; Tiltman & Friedell, 1971; Pamukcu
et al., 1976; Hicks & Chowaniec, 1978). In
previous ultrastructural investigations,
pleomorphic microvilli and a filamentous
or beaded glycocalyx have been identified
as morphological markers of neoplastic
transformation in the bladder (Hicks &
Wakefield, 1976; Newman & Hicks, 1977;
Shirai et al., 1978). Our present studies
demonstrate that these structures may
exhibit a striking variety of form, and
that they occurred in both the one
"spontaneous" and the MNU-induced rat
bladder tumours. Although pleomorphic
microvilli have been consistently re-
garded as a characteristic marker for neo-
plastic transformation in the urothelium
(Newman & Hicks, 1977; Jacobs et al.,
1977; Shirai et al., 1978) a recent report
describes their occasional presence in
severe reversible hyperplasia (Fukushima
et al., 1981). An occasional cell with
microvilli is sometimes found in urine
sediments from healthy humans with no
neoplastic disease of the urinary tract,
but such cells are far more numerous in
sediments from bladder-cancer patients
(Newman & Hicks, 1981). Both qualita-
tive and quantitative changes are thus
associated with neoplastic transformation
and, rather than placing absolute reliance
on any single phenotypic marker, both
must be assessed when judging the
probability of the urothelium progressing
to neoplasia.
In conclusion, the present results with
fractionated doses of MNU, together with
previous reports from this laboratory
(Hicks & Chowaniec, 1977; Hicks et al.,
1978; Hicks, 1980), demonstrate a multi-
step process of carcinogenesis in the
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bladder. This suggests that bladder
carcinogenesis has many characteristics
in common with the classical multistage
model derived from studies on the mouse
epidermis (Berenblum, 1974). Evidence
has accumulated that the multistage
model is applicable to carcinogenesis in
the liver (Peraino et at., 1973; Farber &
Solt, 1978; Pitot et al., 1978) and pos-
sibly in the colon (Reddy et al., 1978) and
lung (Witschi & Lock, 1978). Further-
more, epidemiological studies suggest that
the development of many human carcino-
mas also follows a temporal sequence of
events (Peto, 1977). The multistage model
thus provides a useful framework within
which to analyse the development of
neoplasia in epithelial tissues.
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